Cargando…

Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence

OBJECTIVE: To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma. METHODS: Participants were treated with oral propranolol three times daily, with inpatient monitoring of adverse effects. The starting dosage was 2 mg/kg per day, which had...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Qiang, Li, Qin, Zhang, Bin, Yu, Wenlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657346/
https://www.ncbi.nlm.nih.gov/pubmed/23519547
http://dx.doi.org/10.1007/s00383-013-3283-y
_version_ 1782270128802496512
author Xiao, Qiang
Li, Qin
Zhang, Bin
Yu, Wenlin
author_facet Xiao, Qiang
Li, Qin
Zhang, Bin
Yu, Wenlin
author_sort Xiao, Qiang
collection PubMed
description OBJECTIVE: To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma. METHODS: Participants were treated with oral propranolol three times daily, with inpatient monitoring of adverse effects. The starting dosage was 2 mg/kg per day, which had been for the remaining duration of treatment. Therapy duration was planned for 4–6 months; if there was significant relapse, the period of treatment was extended. A photograph based severity scoring assessment was performed by three observers to evaluate efficacy by visual analog scale (VAS). RESULTS: Sixty-one infants [median age 3.3 (1.2–8.1) months] were included in the study. The median follow-up-time was 15 (6–20) months and 53 patients completed treatment at a median age of 10.3 (8.4–18.1) months, after a duration of 8.5 (4.5–14) months. In all patients, there was significant fading of color [with a VAS of −9 (−6 to −9) after 6 months] and significant decrease in size of the infantile hemangiomas [with a VAS of −8 (−3 to −10) after 6 months]. We did not observe any life-threatening adverse effects. The therapy was interrupted due to temporary aggravation of pre-existing bronchial asthma in one child. Four cases presented partial recurrences. CONCLUSIONS: Oral propranolol 2 mg/kg per day was a well-tolerated and effective treatment, mild adverse effects, and low recurrence for infantile hemangiomas. Propranolol should now be used as a first-line treatment in hemangiomas when intervention is required. Also, prospective studies should be needed in determining the most effective treatment dosage, optimum treatment duration, and exact mechanism of action of propranolol in future.
format Online
Article
Text
id pubmed-3657346
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-36573462013-05-20 Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence Xiao, Qiang Li, Qin Zhang, Bin Yu, Wenlin Pediatr Surg Int Original Article OBJECTIVE: To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma. METHODS: Participants were treated with oral propranolol three times daily, with inpatient monitoring of adverse effects. The starting dosage was 2 mg/kg per day, which had been for the remaining duration of treatment. Therapy duration was planned for 4–6 months; if there was significant relapse, the period of treatment was extended. A photograph based severity scoring assessment was performed by three observers to evaluate efficacy by visual analog scale (VAS). RESULTS: Sixty-one infants [median age 3.3 (1.2–8.1) months] were included in the study. The median follow-up-time was 15 (6–20) months and 53 patients completed treatment at a median age of 10.3 (8.4–18.1) months, after a duration of 8.5 (4.5–14) months. In all patients, there was significant fading of color [with a VAS of −9 (−6 to −9) after 6 months] and significant decrease in size of the infantile hemangiomas [with a VAS of −8 (−3 to −10) after 6 months]. We did not observe any life-threatening adverse effects. The therapy was interrupted due to temporary aggravation of pre-existing bronchial asthma in one child. Four cases presented partial recurrences. CONCLUSIONS: Oral propranolol 2 mg/kg per day was a well-tolerated and effective treatment, mild adverse effects, and low recurrence for infantile hemangiomas. Propranolol should now be used as a first-line treatment in hemangiomas when intervention is required. Also, prospective studies should be needed in determining the most effective treatment dosage, optimum treatment duration, and exact mechanism of action of propranolol in future. Springer-Verlag 2013-03-22 2013 /pmc/articles/PMC3657346/ /pubmed/23519547 http://dx.doi.org/10.1007/s00383-013-3283-y Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Xiao, Qiang
Li, Qin
Zhang, Bin
Yu, Wenlin
Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
title Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
title_full Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
title_fullStr Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
title_full_unstemmed Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
title_short Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
title_sort propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657346/
https://www.ncbi.nlm.nih.gov/pubmed/23519547
http://dx.doi.org/10.1007/s00383-013-3283-y
work_keys_str_mv AT xiaoqiang propranololtherapyofinfantilehemangiomasefficacyadverseeffectsandrecurrence
AT liqin propranololtherapyofinfantilehemangiomasefficacyadverseeffectsandrecurrence
AT zhangbin propranololtherapyofinfantilehemangiomasefficacyadverseeffectsandrecurrence
AT yuwenlin propranololtherapyofinfantilehemangiomasefficacyadverseeffectsandrecurrence